Kidney transplant. Kidney transplant status
Conditions
Interventions
Intervention 1: In control group placebo will administered one dose before transplantation and then twice per day from day one to five after transplantation. Intervention 2: In intervention group 600
Prevention
In control group placebo will administered one dose before transplantation and then twice per day from day one to five after transplantation
In intervention group 600 mg acetylcysteine will administered one dose before transplantation and then twice per day from day one to five after transplantation
Sponsors
Shahid Beheshti Medical University, School of Pharmacy and Shahid Labbafinejad Medical Center and Ur
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: inclusion criteria: kidney transplant recepients from deceased-donor; over 18 years of age exclusion criteria: Recent stroke; hyperoxaluria; Sensitivity to sulfonamides; PRA>30%; Second transplantation; Less then 2 cc urine volume before transplantation
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine and plasma NGAL. Timepoint: pre-transplantation, dar 1 and 5 after transplantation. Method of measurement: ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Need for dialysis in the firs week post transplantation or creatinine reduction ratio less than 10% per day in 3 consecutive days after transplantation. Timepoint: daily. Method of measurement: laboratory reports for SrCr and clinical sign and symptoms for dialysis. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAtieh Modarresi
School of pharmacy, Shahid Beheshti University of Medical Sciences
Outcome results
None listed